Dear Editor,Collecting duct carcinoma(CDC)or Bellini carcinoma originates in the distal collecting ducts.CDC is a markedly aggressive subtype of renal cell carcinoma and accounts for less than 1%of all renal cell carc...Dear Editor,Collecting duct carcinoma(CDC)or Bellini carcinoma originates in the distal collecting ducts.CDC is a markedly aggressive subtype of renal cell carcinoma and accounts for less than 1%of all renal cell carcinomas[1].We described a patient with CDC and psoriasis,who showed complete response(CR)after being treated with combination therapy of nivolumab and ipilimumab(NI).The study was conducted in accordance with and approved by the Ethics Committee of Yamagata University Faculty of Medicine(approval no.2019-35).The need for patient consent was waived by the same institutional review board;all the patients provided written informed consents.展开更多
Dear Editor,Several Phase 3 trials have demonstrated the efficacy of immune checkpoint inhibitor(ICI)-based combination therapies in the treatment of advanced clear cell renal cell carcinoma(RCC)[1-5].However,there is...Dear Editor,Several Phase 3 trials have demonstrated the efficacy of immune checkpoint inhibitor(ICI)-based combination therapies in the treatment of advanced clear cell renal cell carcinoma(RCC)[1-5].However,there is still no well-defined adequate treatment for patients who experience disease progression after initial ICI-based combination therapy.展开更多
Metabolic syndrome is a long-term complication of systemic chemotherapy for testicular germ cell tumor(TGCT).It is believed to be caused by secondary hypogonadism or toxic medicines because of orchidectomy followed by...Metabolic syndrome is a long-term complication of systemic chemotherapy for testicular germ cell tumor(TGCT).It is believed to be caused by secondary hypogonadism or toxic medicines because of orchidectomy followed by systemic chemotherapy.In this study,changes in the body composition of patients over time were quantitatively analyzed up to 24 months after chemotherapy.This study retrospectively analyzed 44 patients with TGCT who underwent chemotherapy at our institution from January 2008 to December 2016.Subcutaneous and visceral fat areas and psoas and skeletal muscle areas were measured by computed tomography before and immediately after chemotherapy as well as 3 months,6 months,12 months,and 24 months after chemotherapy.The subcutaneous and visceral fat indices and psoas and skeletal muscle indices were calculated as each area divided by body height squared.The total fat area had already significantly increased 3 months after the initiation of chemotherapy(P=0.004).However,it did not return to prechemotherapeutic levels even at 24 months after chemotherapy.The skeletal muscle area was significantly decreased at the end of chemotherapy(P<0.001);however,the value returned to baseline within 12 months.In multivariable analysis,the prechemotherapeutic skeletal muscle index and number of chemotherapy cycles were independently associated with the reduction of skeletal muscle at the end of chemotherapy(P=0.001 and P=0.027,respectively).In patients with TGCT,skeletal muscle mass decreased during chemotherapy and recovered within 12 months,whereas fat mass progressively increased from the initiation of chemotherapy until 24 months after chemotherapy.展开更多
文摘Dear Editor,Collecting duct carcinoma(CDC)or Bellini carcinoma originates in the distal collecting ducts.CDC is a markedly aggressive subtype of renal cell carcinoma and accounts for less than 1%of all renal cell carcinomas[1].We described a patient with CDC and psoriasis,who showed complete response(CR)after being treated with combination therapy of nivolumab and ipilimumab(NI).The study was conducted in accordance with and approved by the Ethics Committee of Yamagata University Faculty of Medicine(approval no.2019-35).The need for patient consent was waived by the same institutional review board;all the patients provided written informed consents.
文摘Dear Editor,Several Phase 3 trials have demonstrated the efficacy of immune checkpoint inhibitor(ICI)-based combination therapies in the treatment of advanced clear cell renal cell carcinoma(RCC)[1-5].However,there is still no well-defined adequate treatment for patients who experience disease progression after initial ICI-based combination therapy.
文摘Metabolic syndrome is a long-term complication of systemic chemotherapy for testicular germ cell tumor(TGCT).It is believed to be caused by secondary hypogonadism or toxic medicines because of orchidectomy followed by systemic chemotherapy.In this study,changes in the body composition of patients over time were quantitatively analyzed up to 24 months after chemotherapy.This study retrospectively analyzed 44 patients with TGCT who underwent chemotherapy at our institution from January 2008 to December 2016.Subcutaneous and visceral fat areas and psoas and skeletal muscle areas were measured by computed tomography before and immediately after chemotherapy as well as 3 months,6 months,12 months,and 24 months after chemotherapy.The subcutaneous and visceral fat indices and psoas and skeletal muscle indices were calculated as each area divided by body height squared.The total fat area had already significantly increased 3 months after the initiation of chemotherapy(P=0.004).However,it did not return to prechemotherapeutic levels even at 24 months after chemotherapy.The skeletal muscle area was significantly decreased at the end of chemotherapy(P<0.001);however,the value returned to baseline within 12 months.In multivariable analysis,the prechemotherapeutic skeletal muscle index and number of chemotherapy cycles were independently associated with the reduction of skeletal muscle at the end of chemotherapy(P=0.001 and P=0.027,respectively).In patients with TGCT,skeletal muscle mass decreased during chemotherapy and recovered within 12 months,whereas fat mass progressively increased from the initiation of chemotherapy until 24 months after chemotherapy.
